Efficacy of entecavir in chronic hepatitis b patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage

Hepatology

Volumn 51, Issue 4, 2010, Pages 1185-1189

  Wu, I Chin ^a,b   Lai, Ching Lung ^c   Bui Han, Steven Huy ^d   Han, Kwang Hyup ^e   Gordon, Stuart C ^f   Chao, You Chen ^g   Tan, Chee Kiat ^h   Sievert, William ⁱ   Tanwandee, Tawesak ^j   Xu, Dong ^k   Neo, Boon Leong ^k   Chang, Ting Tsung ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Yonsei University College of Medicine   (South Korea)

^f HENRY FORD HOSPITAL   (United States)

^g TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^h SINGAPORE GENERAL HOSPITAL   (Singapore)

ⁱ MONASH UNIVERSITY   (Australia)

^j MAHIDOL UNIVERSITY   (Thailand)

^k BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CHRONIC HEPATITIS B; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SCREENING TEST; SEROCONVERSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOPSY; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LIVER; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 77950609092     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23424     Document Type: Article

References (25)

1. Lok ASF, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2007;45:507-539.
2. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263-283.
3. Keeffe EB, Dieterich DT, Han SHB, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008;6:1315-1341.
4. ACT-HBV Asia-Pacific Steering Committee Members. Chronic hepatitis B: a treatment alert. Liver Int 2006;26(Suppl. 2):47-58.
5. Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver disease: prospective cohort study. BMJ 2004;328:983-989.
6. Yuen MF, Yuan HJ, Wong DKH, Yuen JCH, Wong WM, Chan AOO, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005;54:1610-1614.
7. Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008;48(Suppl 1):S2-S19.
8. Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 2007;147:58-61.
9. Sherman M, Shafran S, Burak K, Doucette K, Wong W, Girgrah N, et al. Management of chronic hepatitis B: consensus guidelines. Can J Gastro-enterol 2007;21 (Suppl C):5C-24C. (Pubitemid 47162250)
10. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000;342:1266-1271.
11. Kumar M, Sarin SK, Hissar S, Pande C, Sakhuja P, Sharma BC, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008;134:1376-1384.
12. Tsang PS, Trinh H, Garcia RT, Phan JT, Ha NB, Nguyen H, et al. Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels. Clin Gastroenterol Hepatol 2008;6:569-574.
13. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007;47:760-767.
14. Yang LM, Xu KC, Zhao YL, Wu ZR, Chen TF, Qin ZY, et al. Clinical significance of liver biopsy in chronic hepatitis B patients with persistently normal transaminase. Chin J Dig Dis 2002;3:150-153.
15. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. HEPATOLOGY 2002;36:186-194.
16. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. HEPATOLOGY 1999;30:770-774.
17. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. HEPATOLOGY 2006;44:1656-1665.
18. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010. (Pubitemid 43357804)
19. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020. (Pubitemid 43357805)
20. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudine-refractory HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-2049. (Pubitemid 43816960)
21. Park BK, Park YN, Ahn SH, Lee KS, Chon CY, Moon YM, et al. Long-term outcome of chronic hepatitis B based on histological grade and stage. J Gastroenterol Hepatol 2007;22:383-388.
22. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. HEPATOLOGY 2006; 43:S173-S181.
23. Hui CK, Leung N, Yuen ST, Zhang HY, Leung KW, Lu L, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. HEPATOLOGY 2007;46:395-401. (Pubitemid 47344774)
24. Andreani T, Serfaty L, Mohand D, Dernaika S, Wendum D, Chazouilleres O, et al. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. Clin Gastroenterol Hepatol 2007;5:636-641.
25. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242.